Clinical Trial Update: The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial sponsored by Brigham and Women's Hospital evaluated a long-acting insulin injection to reduce C-reactive protein in patients with Type 2 diabetes;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin (long-acting) (insulin)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Type 2 Diabetes | Phase 4 | Status: TERMINATED | Results posted: 2010-11-25